Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 42.38% is 69% below its 3-year average of 134.76%, near the low end of its 3-year range (39.13%–356.49%).
As of the fiscal period ended Tuesday, June 30, 2026. 62.05% below its 12-month average of 111.68%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 42.38%.
DEBT TO ASSETS RATIO
42.38%
DEBT TO ASSETS RATIO AVG TTM
111.68%
DEBT TO ASSETS RATIO AVG 3Y
134.76%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-62.05%
CURRENT VS 3Y AVG
-68.55%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 584 covered companies
CURRENT VS SECTOR MEDIAN
+42280.33%
vs the sector median at left
Liminatus Pharma, Inc. Class A Common Stock
Market Cap
$5.20M
Debt to Assets Ratio
42.38%
TTM Avg
111.68%
3Y Avg
134.76%
5Y Avg
N/A
Market Cap
$5.29M
Debt to Assets Ratio
0.15%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.31M
Debt to Assets Ratio
0.49%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.10M
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.96M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.57M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $5.20M | 42.38% | 111.68% | 134.76% | N/A |
| Imunon, Inc. (IMNN)vs › | $5.27M | 0.52% | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.29M | 0.15% | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.31M | 0.49% | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.10M | 0.25% | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.34M | 0.00% | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.37M | 0.14% | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.96M | 0.00% | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.57M | 0.00% | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.73M | 0.02% | N/A | N/A | N/A |
Debt/Assets
42.4%
Debt/Equity
4.80
Current Ratio
1.12
Interest Coverage
-13.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 42.38% |
| 2026-03-31 | 51.70% |
| 2025-12-31 | 281.30% |
| 2025-09-30 | 107.46% |
| 2025-06-30 | 75.57% |
| 2024-12-31 | 181.07% |
| 2024-09-30 | 149.02% |
| 2024-06-30 | 106.69% |
| 2024-03-31 | 91.60% |
| 2023-12-31 | 356.49% |
| 2023-09-30 | 39.13% |
